Cannabis and Kratom: More Connected Than the Internet Thinks
The popular claim that cannabis and kratom are pharmacologically unrelated isn't accurate. They share receptor pathways and liver enzymes — here's what the research actually shows.
This article is for educational purposes only. It is not medical advice and is not an endorsement of using either plant, alone or together. See the full note at the end.
Search "cannabis and kratom" and you'll meet the same reassuring sentence again and again: two plants, two completely separate systems, nothing to do with each other. It's a tidy line. It's also not quite what the research shows.
The real biology is messier — and more interesting — than the clichés suggest. There is genuine overlap between how these two plants behave in the body, both at the level of receptors and in the way the liver processes them. Understanding that overlap is exactly what explains why treating them as two unrelated substances is a mistake, and why casually combining them is less predictable than it looks.
The "two different systems" story, and where it breaks down
The popular version goes like this: cannabis acts on the endocannabinoid system through the CB1 and CB2 receptors, while kratom acts on opioid receptors. As a starting point, that's broadly fair.
The problem is that kratom's main alkaloid, mitragynine, is not a clean "opioid-only" molecule. Research describes it as pharmacologically mixed, with activity at opioid, adrenergic, serotonergic, and dopamine receptor subtypes [3]. It is far more promiscuous than the simple framing allows.
And the endocannabinoid system — cannabis's home turf — turns out to be part of the picture too. In rodent studies, mitragynine produced cognitive effects that resembled those of THC and morphine, and those effects were reversed by blocking the CB1 cannabinoid receptor [1]. In other words, at least some of kratom's activity appears to run partly through the same cannabinoid signalling that cannabis engages directly.
A crucial caveat: this is preclinical, animal-model evidence. It tells us something about mechanism, not about what happens in people. But it's enough to retire the idea that the two plants occupy entirely separate biochemical worlds.
Where the overlap gets specific
The shared machinery is not a blanket effect — it shows up in some contexts and not others, which is part of what makes the science credible rather than hand-wavy.
In a 2023 study, cannabinoid signalling was found to contribute to mitragynine's activity against neuropathic pain in animal models, but not against inflammatory pain [2]. The researchers noted that kratom and cannabis are commonly used together, often by people self-treating pain — which is what motivated the question in the first place.
It is worth being clear about what this does and does not establish. It is mechanistic animal research suggesting a shared pathway in one specific type of pain. It is not evidence that either plant, or the combination, is an effective or appropriate treatment for anything in humans.
The metabolic collision: the part worth taking seriously
Beyond receptors, cannabis and kratom also meet in the liver — and this is the most practically relevant overlap.
Both compounds are handled by the same drug-metabolising enzymes, particularly CYP2D6 and CYP3A4. In a rat study, co-administering CBD raised systemic exposure to kratom's alkaloids — roughly doubling mitragynine levels and delaying the time it took to peak [3]. Both CBD and mitragynine are inhibitors of CYP2D6, so each can slow the clearance of the other.
In plain language: when both are present, the body may process kratom more slowly, so the "same amount" can behave differently and less predictably than it would on its own. This is, again, preclinical and based on animals — but it is a mechanistically plausible interaction grounded in known enzyme pathways, not internet folklore.
There's a neat way to frame this for anyone steeped in cannabis culture. The "entourage effect" — the idea that plant compounds can amplify one another — gets celebrated endlessly. Pharmacokinetic interactions are its less glamorous cousin: amplification you didn't ask for and can't easily predict.
What this means, and what it doesn't
This is the part that matters most, so it's worth being blunt.
What the evidence supports: the claim that cannabis and kratom are pharmacologically unrelated is simply inaccurate. They share receptor pathways (including the cannabinoid system) and they compete for the same liver enzymes.
What the evidence does not support: that combining them is beneficial, synergistic in a useful way, safe, or advisable. The findings above come overwhelmingly from cells and rodents. Robust human data on the combination is very limited. Individual responses vary widely, and both plants carry their own considerations — kratom in particular has documented potential for dependence and withdrawal, and product quality and labelling can vary considerably between sellers and batches.
The honest takeaway is that the shared biology is a reason for curiosity and caution, not a green light. The same enzyme interactions described here also apply to many prescription medications, which is precisely why this is not something to navigate by trial and error.
A note on legality and safety
The legal status of kratom varies widely from country to country and can change with little warning, so anyone interested should check their local regulations rather than assume. More importantly, anyone considering use — especially alongside medications, existing health conditions, or pregnancy — should speak with a qualified healthcare professional first.
Disclaimer
This article is provided for general educational and informational purposes only. It does not constitute medical, health, or legal advice, and it is not intended to diagnose, treat, cure, or prevent any condition, nor to encourage the use of any substance. The research discussed is largely preclinical (cell-based and animal studies) and should not be read as evidence of safety or efficacy in humans. Always consult a qualified healthcare professional before making decisions that may affect your health, and comply with the laws applicable in your location.
Sources
- Mitragynine (Kratom)-Induced Cognitive Impairments in Mice Resemble Δ9-THC and Morphine Effects: Reversal by Cannabinoid CB1 Receptor Antagonism. Frontiers in Pharmacology, 2021. frontiersin.org
- Cannabinoid mechanisms contribute to the therapeutic efficacy of the kratom alkaloid mitragynine against neuropathic, but not inflammatory pain. 2023. Available via PubMed Central: pmc.ncbi.nlm.nih.gov
- Pharmacokinetic Interaction of Kratom and Cannabidiol in Male Rats. Pharmaceutics, 2024. Available via PubMed Central: ncbi.nlm.nih.gov